falling prices is nothing new for this stock

AVASTRA (AVS) shareholders were understandably nervous after the company advised the ASX it had halted clinical trials.

Interim analysis this week of an existing long-term animal study on the BioWeld Tube in end-to-end anastomoses (whatever they are) had shown an "unexpected result" in some animals.

Full results will not become available until the end of August so shareholders are going to have to put up with the suspense - unless the company relents and tells all what that "unexpected result" was.

Avastra shares fell off a cliff.

The price hit a new low of 16.5c, down 6.5c for the day.

Falling prices is nothing new for this stock.

It floated at $1 last June, had an opening sale at 99c and
slowly deteriorated.